Efficacy and Safety of Duloxetine Among Individuals With Depressive Disorder in a 12 Weeks Trial
Overview
The aim of this study was to investigate the effects of duloxetine on improvement of brain cortical activity in patients suffering from major depressive disorder using near infrared spectroscopy.
Study Type
- Study Type: Interventional
- Study Design
- Intervention Model: Sequential Assignment
- Primary Purpose: Health Services Research
- Masking: None (Open Label)
- Study Primary Completion Date: September 26, 2016
Interventions
- Drug: Duloxetine
- duloxetine 30 to 60 mg tablets by mouth, QD to BID per day,
Arms, Groups and Cohorts
- Other: intervention
- medication: duloxetine 30 to 60 mg tablets by mouth, QD to BID.
Clinical Trial Outcome Measures
Primary Measures
- Change in Depression severity
- Time Frame: 0-2-4-8-12 weeks
- Hamilton Rating Scale for Depression
Secondary Measures
- Change in Brain cortical activity
- Time Frame: 0-2-4-8-12 weeks
- Using Near Infrared Spectroscopy
Participating in This Clinical Trial
Inclusion Criteria
- HAMD-17 more than 12 points – Participants could understand this study and sign permit – Participants could receive NIRS measurements – Participants could comply with the protocol of the study Exclusion Criteria:
- alcohol or substance abuse within 3 months of the study – ever participate other clinical study related to duloxetine – previous poor treatment effects of duloxetine – concomitant use of MAOi within 14 days – concomitant use of Linezolid – with uncontrolled glaucoma
Gender Eligibility: All
Minimum Age: 20 Years
Maximum Age: 65 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Taichung Veterans General Hospital
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.